Rubicon Research: ₹485 IPO to ₹1,751 — 3.6x in Under a Year

Rubicon Research remains in a strong bullish trend after a sharp post-IPO rally. The ₹1,695 upward-sloping trendline is a key near-term support level, while ₹1,900 remains crucial on the upside. Rubicon Research

has remained in a strong bull run since its October 2025 listing, with the stock delivering substantial gains from its ₹485 issue price. After listing at around ₹620, the stock continued its upward journey and reached a 52-week high of ₹1,899. The company focuses on regulated pharmaceutical markets, particularly the US, with offerings spanning complex formulations, specialty drugs, nasal sprays, drug-device combinations, CDMO services and branded CNS products. The company reports ROE of 19.14% and ROCE of 24.54%, reflecting healthy return ratios. However, the stock trades at premium valuations, with a P/E of 100.73 and P/B of 22.53. Technically, the broader price structure remains bullish. The stock is currently trading near an upward-sloping trendline, which has been supporting the ongoing uptrend. The ₹1,695 level is therefore an important near-term support zone. Sustaining above support trendline could keep the broader bullish structure intact. On the upside, ₹1,900 remains a key level to watch, and a sustained move above this zone could attract renewed momentum. Disclosure: Neither I nor my family members hold any position in the mentioned scrip. This content is shared solely for informational and educational purposes and should not be construed as investment advice or a recommendation to buy or sell.